GSK (GSK) Stock Price, News & Analysis

Company Overview

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer.

Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, businesses with histories stretching back much further. GSK serves patients and healthcare providers around the world. In 2022, its consumer healthcare business was separated and became Haleon.

Key Stats

• Today's Range: $50.13 to $50.80
• 50-Day Range: $46.24 to $51.47
• 52-Week Range: $45.81 to $61.69
• Volume: 2.78 million shs
• Average Volume: 4.23 million shs
• Market Capitalization: $102.13 billion
• P/E Ratio: 17.54
• Dividend Yield: 3.51%
• Price Target: $56.30
• Consensus Rating: Hold

GSK Stock Analysis - MarketRank™

GSK scored higher than 72% of companies evaluated by MarketBeat, and ranked 206th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Hold

Consensus Rating

GSK has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 3 buy ratings, 13 hold ratings, and 3 sell ratings.

Upside Potential

GSK has a consensus price target of $56.30, representing about 11.5% upside from its current price of $50.49.

Amount of Analyst Coverage

GSK has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.39%

Earnings Growth

Earnings for GSK are expected to grow by 4.39% in the coming year, from $4.78 to $4.99 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GSK is 17.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of GSK is 17.54, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

Price to Earnings Growth Ratio

GSK has a PEG Ratio of 2.28. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GSK has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.89% of the float of GSK has been sold short.

Short Interest Ratio / Days to Cover

GSK has a short interest ratio ("days to cover") of 3.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GSK has recently increased by 10.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

GSK pays a meaningful dividend of 3.50%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

GSK does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of GSK is 61.46%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, GSK will have a dividend payout ratio of 35.47% next year. This indicates that GSK will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.42

News Sentiment

GSK has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for GSK this week, compared to 7 articles on an average week.

Search Interest

30 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

20 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GSK insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.00% of the stock of GSK is held by insiders.

Percentage Held by Institutions

15.74% of the stock of GSK is held by institutions.

Company Calendar

• Last Earnings: 7/28/2026
• Record date for 10/8 Dividend: 8/14/2026
• Ex-Dividend for 10/8 Dividend: 8/14/2026
• Dividend Payable: 10/08/2026
• Record date for 1/7 Dividend: 11/13/2026
• Ex-Dividend for 1/7 Dividend: 11/13/2026
• Today: 11/15/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 12/31/2026
• Dividend Payable: 1/07/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:GSK
• CIK: 1131399
• Web: www.gsk.com
• Phone: 442080475000
• Fax: 44-20-8047-7807
• Employees: 66,841
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GSK: $56.30
• High Price Target: $70.00
• Low Price Target: $43.00
• Potential Upside/Downside: +11.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.88
• Trailing P/E Ratio: 17.54
• Forward P/E Ratio: 10.12
• P/E Growth: 2.28
• Net Income: $7.54 billion
• Net Margins: 13.00%
• Pretax Margin: 16.10%
• Return on Equity: 41.41%
• Return on Assets: 11.09%

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 0.86
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $43.07 billion
• Price / Sales: 2.37
• Cash Flow: $5.99 per share
• Price / Cash Flow: 8.43
• Book Value: $12.21 per share
• Price / Book: 4.14

Miscellaneous

• Outstanding Shares: 2,022,710,000
• Free Float: 1,820,435,000
• Market Cap: $102.13 billion
• Optionable: Optionable
• Beta: 0.29